| 1 |
35172577 | Discovery of Anticancer Hybrid Molecules by Supervised Machine Learning Models and in Vitro Validation in Drug Resistant Chronic Myeloid Leukemia Cells. | 2022 Feb 28 |
2 |
| 2 |
35470777 | In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase. | 2022 Apr 26 |
1 |
| 3 |
34508625 | ABL1 and Cofilin1 promote T-cell acute lymphoblastic leukemia cell migration. | 2021 Oct 12 |
1 |
| 4 |
32424388 | Is breaking of a hydrogen bond enough to lead to drug resistance? | 2020 Jun 18 |
1 |
| 5 |
27966954 | Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. | 2017 Jan 12 |
1 |
| 6 |
28338290 | Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia. | 2017 Oct |
1 |
| 7 |
23679864 | Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design. | 2013 Jun 5 |
1 |
| 8 |
20072125 | Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. | 2010 Jan 28 |
1 |
| 9 |
20808434 | Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. | 2010 Aug 16 |
1 |
| 10 |
19164531 | Conformational disturbance in Abl kinase upon mutation and deregulation. | 2009 Feb 3 |
1 |
| 11 |
8590002 | The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct. | 1995 Oct 15 |
1 |
| 12 |
1281542 | Secondary structure of Src homology 2 domain of c-Abl by heteronuclear NMR spectroscopy in solution. | 1992 Dec 15 |
1 |